José Valentín
García Gutiérrez
Profesor/a Asociado/a en CC. de la Salud
Hospital Clinic Barcelona
Barcelona, EspañaPublicacións en colaboración con investigadores/as de Hospital Clinic Barcelona (41)
2024
-
Impact of somatic gene mutations on the risk of thrombosis in myelofibrosis
Leukemia
-
Integrating AIPSS-MF and molecular predictors: A comparative analysis of prognostic models for myelofibrosis
HemaSphere
-
Omicron SARS-CoV-2 infection management and outcomes in patients with hematologic disease and recipients of cell therapy
Frontiers in Oncology, Vol. 14
-
Prognostic value of response to first-line hydroxyurea according to IPSET stratification in essential thrombocythemia
Leukemia
-
ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options
Annals of Hematology, Vol. 103, Núm. 7, pp. 2299-2310
-
The prognostic impact of non-driver gene mutations and variant allele frequency in primary myelofibrosis
American Journal of Hematology
2023
-
Application of IPSET-Thrombosis in 1366 Patients Prospectively Followed from the Spanish Registry of Essential Thrombocythemia
HemaSphere, Vol. 7, Núm. 8, pp. E936
-
Philadelphia-negative chronic myeloproliferative neoplasm follow-up: when the phone rings. Changes during the COVID-19 pandemic and patient satisfaction. Experience in 30 health centers in Spain
Annals of Hematology, Vol. 102, Núm. 2, pp. 447-456
-
Remdesivir or Nirmatrelvir/Ritonavir Therapy for Omicron SARS-CoV-2 Infection in Hematological Patients and Cell Therapy Recipients
Viruses, Vol. 15, Núm. 10
-
Toxicity of Asciminib in Real Clinical Practice: Analysis of Side Effects and Cross-Toxicity with Tyrosine Kinase Inhibitors
Cancers, Vol. 15, Núm. 4
2022
-
Breakthrough infections in MPN-COVID vaccinated patients
Blood Cancer Journal
-
Determinants of early triage for hospitalization in myeloproliferative neoplasm (MPN) patients with COVID-19
American Journal of Hematology
-
Low-risk polycythemia vera treated with phlebotomies: clinical characteristics, hematologic control and complications in 453 patients from the Spanish Registry of Polycythemia Vera
Annals of Hematology, Vol. 101, Núm. 10, pp. 2231-2239
-
Prevention of venous thromboembolism in hematologic neoplasms: an expert consensus from SEHH–SETH
Clinical and Translational Oncology, Vol. 24, Núm. 5, pp. 770-783
-
Real-life analysis on safety and efficacy of asciminib for ponatinib pretreated patients with chronic myeloid leukemia
Annals of Hematology, Vol. 101, Núm. 10, pp. 2263-2270
-
Real-world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea
Cancer, Vol. 128, Núm. 13, pp. 2441-2448
-
Second versus first wave of COVID-19 in patients with MPN
Leukemia
-
Spanish Society of Hematology and Hemotherapy expert consensus opinion for SARS-CoV-2 vaccination in onco-hematological patients
Leukemia and Lymphoma, Vol. 63, Núm. 3, pp. 538-550
-
Tyrosine kinase inhibitor dose reduction during the management ofaccelerated phase chronic myeloid leukemia
Leukemia Research
2021
-
Allogeneic hematopoietic cell transplantation in older myelofibrosis patients: A study of the chronic malignancies working party of EBMT and the Spanish Myelofibrosis Registry
American Journal of Hematology, Vol. 96, Núm. 10, pp. 1186-1194